



## Information on Dividend Payment and Tax Deduction

June 15, 2022

**MAINZ, Germany, June 15, 2022 (GLOBE NEWSWIRE)** — [BioNTech SE](#) (Nasdaq: BNTX, “BioNTech”) informs its shareholders that the dividend will be passed on to the investors of the American Depository Receipts (ADR) (ISIN US09075V1026) by the Bank of New York Mellon on June 17, 2022. The company has already distributed the dividend for shareholders of registered shares of BioNTech SE (ISIN DE000A0V9BC4) on June 7, 2022, after the Annual General Meeting resolved to pay shareholders a special dividend of €2.00 per ordinary share (including shares held in form of American Depository Shares), corresponding to approximately €484.2 million.

Due to legal requirements, both The Bank of New York Mellon SA/NV Frankfurt am Main branch as domestic depository of the BioNTech SE shares (ISIN DE000A0V9BC4) and the German custodians of the ADR holders are obliged to tax capital gains at a tax rate of 26.375%. The tax burden on the ADR dividend will therefore initially be 52.75% for all customers of German banks.

BioNTech would like to draw the attention of its ADR investors to the fact that the second tax deduction by the German custodians can be subsequently reclaimed from the tax office and credited to the ADR holders if the German custodians request individual tax certificates from the Bank of New York Mellon as evidence of the initial tax deduction. Usually, this process should be initiated automatically by the German custodians. If this is not the case, ADR investors can contact their custodian using the attached sample form in German. For this purpose, the details of the beneficial owner (name and address) as well as the affected number of ADRs are required.

In the case of tax-exempted individuals, a single tax deduction of 26.375% will also be made. Here, too, the German custodians must request an individual tax certificate for the initial tax deduction from the Bank of New York Mellon before they are authorized to fully refund the tax deduction to the ADR holders.

### About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit [www.BioNTech.de](http://www.BioNTech.de).

### CONTACTS

#### Investor Relations

Sylke Maas, Ph.D.  
VP Investor Relations & Strategy  
Tel: +49 (0)6131 9084 1074  
E-mail: [investors@biontech.de](mailto:investors@biontech.de)

#### Media Relations

Jasmina Alatovic  
VP Corporate Communications  
E-mail: [Media@biontech.de](mailto:Media@biontech.de)

### Attachment

- [ADR Example Form \(GER only\)](#)